Allogene Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALLO Nasdaq 2836 allogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allogene Therapeutics, Inc.

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Feb 11th, 2026 7:40 am
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Feb 5th, 2026 6:30 am
Allogene Therapeutics (ALLO) Is Up 24.1% After Extended Cash Runway and CAR T Trial Progress - Feb 4th, 2026 4:16 pm
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Jan 26th, 2026 7:40 am
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses - Jan 21st, 2026 3:58 pm
January 2026 Penny Stock Spotlight: Three Promising Picks - Jan 12th, 2026 5:05 am
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - Jan 8th, 2026 6:30 am
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - Dec 15th, 2025 3:39 pm
December 2025 Penny Stocks Worth Watching - Dec 12th, 2025 11:05 am
November 2025's Promising Penny Stocks To Watch - Nov 12th, 2025 11:05 am
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales - Nov 7th, 2025 9:20 am
Allogene Therapeutics Inc (ALLO) Q3 2025 Earnings Call Highlights: Strategic Advances and ... - Nov 6th, 2025 10:11 pm
Allogene Therapeutics: Q3 Earnings Snapshot - Nov 6th, 2025 2:26 pm
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update - Nov 6th, 2025 2:05 pm
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting - Nov 3rd, 2025 7:04 am
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update - Oct 30th, 2025 6:30 am
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Oct 14th, 2025 9:24 am
Allogene Therapeutics Faces Patent Infringement Challenges - Oct 14th, 2025 9:09 am
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - Oct 10th, 2025 10:21 am
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Oct 10th, 2025 8:27 am